BioVie Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a net loss of $5,605,070 and total assets of $11,037,959 as of that date.

Key Highlights

  • Net loss of $5,605,070 for the three months ended September 30, 2026, compared to a net loss of $5,087,557 in the same period of 2025, according to the filing.
  • Total operating expenses of $5,649,932 for the quarter, driven by research and development expenses of $3,337,427 and general and administrative expenses of $2,312,505.
  • Cash and cash equivalents of $7,732,817 as of September 30, 2026, down from $8,977,370 at June 30, 2026.
  • Accumulated deficit of $379,865,723 as of September 30, 2026, up from $374,260,653 at June 30, 2026.
  • 10,724,724 shares of Class A Common Stock outstanding as of November 5, 2026, per the cover page disclosure.
  • Total stockholders' equity of $6,528,658 as of September 30, 2026, compared to $10,270,270 at June 30, 2026.

BioVie's Fiscal First Quarter 2027 Financial Results and Balance Sheet Position

According to the filing, BioVie Inc. (NASDAQ:BIVI) reported total operating expenses of $5,649,932 for the three months ended September 30, 2026, an increase from $5,284,595 in the comparable prior-year quarter. Research and development expenses rose to $3,337,427 from $2,936,370, while general and administrative expenses were $2,312,505, compared to $2,290,881 a year earlier. The company reported no amortization of intangible assets in the current quarter, versus $57,344 in the prior-year period.

The filing disclosed net loss per common share of $(0.68), basic and diluted, for the September 30, 2026 quarter, based on a weighted average of 8,269,338 shares outstanding. This compares to a net loss per share of $(0.98) in the September 30, 2025 quarter, when the weighted average share count was 5,214,355. Interest income declined to $45,830 from $199,027 year over year, contributing to total other income, net, of $44,862 versus $197,038 in the prior-year period.

On the balance sheet, the company reported total current assets of $10,450,757, including a grant receivable of $217,652, down significantly from $2,151,440 at June 30, 2026. Accounts payable and accrued expenses increased to $4,254,927 from $3,704,762 over the same period. Total liabilities stood at $4,509,301. Common shares issued rose to 8,694,224 at September 30, 2026 from 7,545,474 at June 30, 2026, with additional paid-in capital increasing to $386,393,540 from $384,530,198. The filing notes that forward-looking statements in the report are subject to the company's cautionary language regarding risks and uncertainties.

What Was Disclosed

BioVie Inc. filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $5,605,070, total assets of $11,037,959, cash of $7,732,817, and an accumulated deficit of $379,865,723 as of the quarter's end.